EANS-News: AGENNIX AG Agennix AG to Present at German Equity Forum in November
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information
Planegg/Munich (Germany), Princeton, NJ and Houston, TX, November 16, 2011 (euro
adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the
Company will give a presentation at the upcoming German Equity Forum
(Eigenkapitalforum) in Frankfurt, Germany. The German Equity Forum is an
investor conference hosted by the Deutsche Boerse and KfW SME Bank. The
Company's presentation is scheduled for Tuesday, November 22, 2011 at 12:45 CET,
Room Madrid, at the Congress Center Messe Frankfurt.
About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company's most advanced program is talactoferrin, an
oral immunotherapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer and in severe
sepsis. Talactoferrin is currently in Phase III clinical trials in non-small
cell lung cancer and in a Phase II/III trial in severe sepsis. Other clinical
development programs include RGB-286638, a multi-targeted kinase inhibitor in
Phase I testing for cancer, and a topical gel form of talactoferrin for diabetic
foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company
has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix Web site at
www.agennix.com.
This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. There can be no
guarantee that the Company will have sufficient cash to fund operations into the
second half of 2012. The achievement of positive results in early stage
clinical studies does not ensure that later stage or large scale clinical
studies will be successful. Even if the results from our later stage trials
with talactoferrin, including the ongoing FORTIS-M trial in non-small cell lung
cancer, are considered positive, there can be no guarantee that they will be
sufficient to gain marketing approval in the United States or any other country,
and regulatory authorities may require additional information, data and/or
further pre-clinical or clinical studies to support approval. In such event,
there can be no guarantee that the Company will have or be able to obtain the
financial resources to conduct any such additional studies or that such studies
will yield results sufficient for approval. Forward-looking statements speak
only as of the date on which they are made and Agennix undertakes no obligation
to update these forward-looking statements, even if new information becomes
available in the future.
Agennix(TM) is a trademark of the Agennix group.
Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com
In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com
Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu
Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English